LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy Proceeds will be used to advance the Company’s IMANs into clinical trialsRaise underpins strong pre-clinical data demonstrating dual mechanism of action of LIfT’s IMANS London, 24 September 2024–...